Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advised Equinor in connection with its investment in Medfield Diagnostics
Mandate

Vinge advised Equinor in connection with its investment in Medfield Diagnostics

November 21, 2018 Capital Markets and Public M&A

Vinge advised Equinor Technology Ventures AS (”Equinor”) in connection with its acquisition in Medfield Diagnostics Aktiebolag (publ) (“Medfield”).

The investment will be made through a directed issue to Equinor as well as a rights issue of shares. Medfield is listed on Spotlight.
Equinor ASA is a global energy company with more than 20,000 employees and business in more than 30 countries. Equinor is the largest oil and gas operator in Norway, one of the largest offshore operators globally and has a growing portfolio of renewable assets in wind and solar power.

Equinor Technology Ventures AS invests in technology companies with major implementation potential in the company’s core business. Since its establishment, ETV has invested in more than 60 companies and financed over 260 product developments.

Vinge’s team consisted of Dain Hård Nevonen, Peter Sundgren, Rikard Lindahl, Amanda Knutsson and Peter Issa. 

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

 Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

 Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025